⚡ KEY INSIGHT
Moderna’s mRNA platform faces regulatory and messaging challenges that could reshape how AI-designed personalized treatments reach patients.
Moderna is navigating a political and semantic minefield as it pivots from traditional vaccines to individualized neoantigen treatments—AI-designed therapies tailored to each patient’s tumor profile. The terminology shift reflects deeper challenges: vaccine skepticism is forcing the company to rebrand its mRNA technology despite its proven efficacy. This naming dilemma highlights how perception, regulation, and nomenclature can impact adoption of cutting-edge biotech innovations, even when the underlying science remains sound.